�If the lessons being learned by scientists more or less the dying of the last great North American ice piece of paper are rectify, estimates of global sea level heighten from a melting Greenland ice sheet may be seriously underestimated.
Writing in the journal Nature Geoscience, a team of researchers lED by University of Wisconsin-Madison geologist Anders Carlson reports that sea level rise from greenhouse-induced warming of the Greenland ice weather sheet could be double or triple stream estimates over the side by side century.
"We're non talking around something catastrophic, but we could examine a practically bigger reception in footing of ocean level from the Greenland ice sheet over the next century years than what is currently predicted," says Carlson, a UW-Madison professor of geology and geophysics. Carlson worked with an outside team of researchers, including Allegra LeGrande from the NASA Center for Climate Systems at Columbia University, and colleagues at the Woods Hole Oceanographic Institution, the California Institute of Technology, University of British Columbia and University of New Hampshire.
Scientists have yet to agree on how much melting of the Greenland ice sheet - a terrestrial ice mass encompassing 1.7 trillion square kilometers - will contribute to changes in sea level. One cause, Carlson explains, is that in recorded history there is no precedent for the influence of climate change on a massive ice sheet.
"We've never seen an internal-combustion engine sheet go away before, just here we have a record," says Carlson of the new study that combined a powerful information processing system model with marine and terrestrial records to provide a shot of how fast ice sheets can buoy melt and raise sea level in a heater world.
Carlson and his group were able-bodied to get on the lessons of the disappearance of the Laurentide ice sheet, the last gravid ice mass to underwrite much of the northern hemisphere. The Laurentide methedrine sheet, which encompassed large parts of what ar now Canada and the United States, began to melt some 10,000 years agone in reply to increased solar radiation in the northern cerebral hemisphere due to a cyclic change in the orientation of the Earth's axis. It experient two speedy pulses of melting - one 9,000 age ago and another 7,600 age ago - that caused global sea level to rise by more than half an inch per year.
Those pulses of melt, according to the new study, occurred when summer air temperatures were similar to what are predicted for Greenland by the end of this hundred, a finding the suggests estimates of global sea level uprise due to a warming world mood may be seriously underestimated.
The most recent estimates of sea level rise due to melt of the Greenland water ice sheet by the Intergovernmental Panel on Climate Change (IPCC) suggest a maximum sea layer rise during the adjacent 100 old age of nearly 1 to 4 inches. That estimate, Carlson and his colleagues note, is based on limited data, mostly from the last decade, and contrasts sharply with results from computing machine models of future clime, casting dubiety on stream estimates of change in sea layer due to melting ice sheets.
According to the raw study, rising sea levels up to a one-third of an inch per year or 1 to 2 feet over the course of a century are possible.
Even slight rises in worldwide sea level are problematic as a significant share of the world's human population - hundreds of millions of people - lives in areas that can be affected by rising seas.
"For planning purposes, we should see the IPCC projections as cautious," Carlson says. "We suppose this is a very low estimate of what the Greenland ice sheet will kick in to sea level."
The authors of the new Nature Geoscience report were able to document the retreat of the Laurentide ice rink sheet and its contributions to changes in sea level by measuring how long rocks once covered by frappe have been exposed to cosmic radiation, estimates of ice retreat based on radiocarbon dates from organic material as well as changes in ocean salinity.
In addition to Carlson and LeGrande, co-authors of the study, which was funded primarily by the National Science Foundation, are Gavin A. Schmidt of Columbia University, Delia W. Oppo of the Woods Hole Oceanographic Institution, Rosemarie E. Came of the California Institute of Technology, Faron S. Anslow of the University of British Columbia, Joseph M. Licciardi of the University of New Hampshire and Elizabeth A. Obbink of UW-Madison.
Terry Devitt
Source: Anders Carlson
University of Wisconsin-Madison
View drug data on Allegra.
More info
Wednesday, 3 September 2008
Thursday, 14 August 2008
Christian Bale Won't Face Assault Charges, Officials Say
British prosecutors announced Thursday (August 14) that "Dark Knight" star Christian Bale will non face charges related to an alleged assault on his mother and sister in London last calendar month, according to The Associated Press.
The alleged incident took place at the actor's hotel on the night of the film's London premiere, according to Bale's mother, Jenny, and sister Sharon, wHO made the report at a police force station in Hampshire.
Bale has denied the allegation.
"Christian Bale attended a London police force station on a voluntary basis in order to assist with an allegation that has been made against him to the police by his mother and sister," the actor's spokesperson aforementioned in a statement at the time. "Mr. Bale, who denies the allegation, co-operated passim, gave his account in full of the events in question, and has left the station without any charge being made against him by the police."
The Crown Prosecution Service said there was deficient evidence for a "realistic prospect of conviction" and has asked that London police accept no further action against Bale, according to the AP.
British sheet The Sun reported that police waited a day to question Bale, to allow the actor time to attend the premiere of the film. Bale was questioned for several hours at a law station before being released on bail.
Prosecutors said the decision non to prosecute the typesetter's case was based in part on the feelings of Bale's mother and sister, the AP reported.
More info
Wednesday, 6 August 2008
FDA Advisory Committee Recommends Approval Of ACTEMRA(R) (tocilizumab) For The Treatment Of Rheumatoid Arthritis
�Roche announced that the
Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA)
by a near unanimous (ci) vote recommended approval of ACTEMRA(R)
(tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal
antibody, for reducing the signs and symptoms in adults with moderate to
severe creaky arthritis (RA).
"The committee's overwhelmingly positive recommendation brings ACTEMRA
one step closer to becoming available to patients world Health Organization suffer from the
terrible and debilitating symptoms associated with RA," said Kenneth Bahrt,
M.D., Global Medical Director, Autoimmunity, Roche. "Based on the strength
of the data presented, and the incontrovertible recommendation by the committee, we
are hopeful that the FDA will approve ACTEMRA for the treatment of RA and
provide a new option to patients wHO are not achieving tolerable symptom
relief with electric current therapies."
The committee's vote was made after Roche presented results from fivesome
Phase III clinical trials. The clinical development curriculum was designed to
judge the personal effects of ACTEMRA on signs and symptoms of RA, physical
subprogram, progression of structural harm, and health-related quality of
life. Of these five-spot studies, trey trials were conducted in patients with
inadequate response to disease modifying anti-rheumatic drugs (DMARDs), one
trial was conducted in patients who failed anti-tumor mortification factor (TNF)
therapy, and one monotherapy study comparison ACTEMRA to methotrexate, a
current criterion of care, was besides conducted. Results of these studies
demonstrated that intervention with ACTEMRA -- solitary or in combination with
methotrexate or other DMARDs -- significantly reduced RA signs and
symptoms, careless of premature therapy or disease severeness, compared with
current DMARDs.
About ACTEMRA (tocilizumab)
ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting
monoclonal antibody. Studies suggest that reducing the activity of IL-6,
one of various key cytokines involved in the incitive process, crataegus oxycantha
reduce inflaming of the joints and relieve certain systemic effects of
RA. The all-embracing clinical development program conducted by Roche includes
five-spot clinical studies and has enrolled more than than 4,000 patients in 41
countries, including the United States. Five Phase III studies ar
completed and have reported meeting their primary endpoints. The LITHE
trial evaluating ACTEMRA in RA is an ongoing two-year cogitation and is expected
to report make out data evaluating the effects of ACTEMRA on the inhibition
of structural articulation damage in 2009. ACTEMRA is awaiting approval in the
United States and Europe.
ACTEMRA is section of a co-development understanding with Chugai, a Japanese
company. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy
for Castleman's disease; in April 2008, additional indications for
rheumatoid arthritis, puerile idiopathic arthritis and systemic-onset
juvenile idiopathic arthritis were also approved in Japan.
The good adverse events reported in ACTEMRA clinical trials include
serious infections, diverticular perforations, and hypersensitivity
reactions including anaphylaxis. The most
Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA)
by a near unanimous (ci) vote recommended approval of ACTEMRA(R)
(tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal
antibody, for reducing the signs and symptoms in adults with moderate to
severe creaky arthritis (RA).
"The committee's overwhelmingly positive recommendation brings ACTEMRA
one step closer to becoming available to patients world Health Organization suffer from the
terrible and debilitating symptoms associated with RA," said Kenneth Bahrt,
M.D., Global Medical Director, Autoimmunity, Roche. "Based on the strength
of the data presented, and the incontrovertible recommendation by the committee, we
are hopeful that the FDA will approve ACTEMRA for the treatment of RA and
provide a new option to patients wHO are not achieving tolerable symptom
relief with electric current therapies."
The committee's vote was made after Roche presented results from fivesome
Phase III clinical trials. The clinical development curriculum was designed to
judge the personal effects of ACTEMRA on signs and symptoms of RA, physical
subprogram, progression of structural harm, and health-related quality of
life. Of these five-spot studies, trey trials were conducted in patients with
inadequate response to disease modifying anti-rheumatic drugs (DMARDs), one
trial was conducted in patients who failed anti-tumor mortification factor (TNF)
therapy, and one monotherapy study comparison ACTEMRA to methotrexate, a
current criterion of care, was besides conducted. Results of these studies
demonstrated that intervention with ACTEMRA -- solitary or in combination with
methotrexate or other DMARDs -- significantly reduced RA signs and
symptoms, careless of premature therapy or disease severeness, compared with
current DMARDs.
About ACTEMRA (tocilizumab)
ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting
monoclonal antibody. Studies suggest that reducing the activity of IL-6,
one of various key cytokines involved in the incitive process, crataegus oxycantha
reduce inflaming of the joints and relieve certain systemic effects of
RA. The all-embracing clinical development program conducted by Roche includes
five-spot clinical studies and has enrolled more than than 4,000 patients in 41
countries, including the United States. Five Phase III studies ar
completed and have reported meeting their primary endpoints. The LITHE
trial evaluating ACTEMRA in RA is an ongoing two-year cogitation and is expected
to report make out data evaluating the effects of ACTEMRA on the inhibition
of structural articulation damage in 2009. ACTEMRA is awaiting approval in the
United States and Europe.
ACTEMRA is section of a co-development understanding with Chugai, a Japanese
company. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy
for Castleman's disease; in April 2008, additional indications for
rheumatoid arthritis, puerile idiopathic arthritis and systemic-onset
juvenile idiopathic arthritis were also approved in Japan.
The good adverse events reported in ACTEMRA clinical trials include
serious infections, diverticular perforations, and hypersensitivity
reactions including anaphylaxis. The most
Friday, 27 June 2008
Paul Ellis and Craig Padilla
Artist: Paul Ellis and Craig Padilla
Genre(s):
Ambient
Discography:
Echo System
Year: 2004
Tracks: 7
Voters Report Being Irritated and Entertained by New McCain Girl Video
Thursday, 19 June 2008
Careful Daddy, That's a Live One!
We're told new daddy Casey Aldridge was so nervous the first time he held his daughter, he told the family he was scared he'd drop her!
TMZ spies say that Casey and Mama Lynne were the only ones in the OR when Maddie was born -- Brit Brit waited outside anxiously. We hear that the family is thrilled that baby Maddie is "happy, healthy and gorgeous" and our source says the family is closer than ever.
Jamie Lynn is expected to remain in the hospital for a few days, but big sis is already back at the house with her fast food fix.
See Also
TMZ spies say that Casey and Mama Lynne were the only ones in the OR when Maddie was born -- Brit Brit waited outside anxiously. We hear that the family is thrilled that baby Maddie is "happy, healthy and gorgeous" and our source says the family is closer than ever.
Jamie Lynn is expected to remain in the hospital for a few days, but big sis is already back at the house with her fast food fix.
See Also
Thursday, 12 June 2008
A Perpetual Dying Mirror
Artist: A Perpetual Dying Mirror
Genre(s):
Metal: Death,Black
Discography:
Towards A Constellation View
Year: 1999
Tracks: 9
Thursday, 29 May 2008
Reviews Are In For Indiana Jones
The first public screening of 'Indiana Jones and the Kingdom of the Crystal Skull' has concluded at the 61st Canne Film Festival, with reviewers predominantly giving the action adventure flick the thumbs up. Following intense scrutiny about whether the series warranted a new addition, 19 years after the last film was made, central star Harrison Ford and filmmakers Steven Speilberg and George Lucas were all smiles as the movie commenced its first public screening. Variety reports that the film "met with a 3½-minute standing ovation - nowhere near a festival record, but a reaction of respect, appreciation for the film's craftsmanship and its nostalgic sensibility and style." Christie Lemire from The Associated Press wrote that although "draggy and repetitive in the middle", 'Kingdom' "dives headfirst into the iconography of the franchise, which will bring a smile to your face and warm you with nostalgia. It's admittedly a pleasure to see Harrison Ford back in the role." The Los Angeles Times' movie critic, Kenneth Turan states, "When you think about it, all the pre-release interest the film has generated is not completely rational. Given its cast, crew and pedigree, it was likely to fall within a very narrow range in terms of quality, and be either a worse- or better-than-average Indiana Jones film. It turns out it's one of the good ones, and everyone involved can breathe a sigh of relief."Photo courtesy of Lucasfilm.
Subscribe to:
Posts (Atom)